Literature DB >> 26415321

RENAL CELL CARCINOMA METASTASIS TO THE SINONASAL CAVITY: CASE REPORT.

Marijan Kovačić, Ana Krvavica, Milan Rudić.   

Abstract

Renal cell carcinoma accounts for 3% of all adult malignant tumors. Common sites of metastases are lungs, bone, liver, brain and adrenal glands. Metastatic disease to the head and neck ranges from 15% to 30%. The 5-year survival rate after nephrectomy is 60%-75%, but with multiorgan metastases the 5-year survival rate is significantly lower, 0-7%. A case is presented of a female patient diagnosed with renal cell carcinoma metastases to the paranasal sinuses, diagnosed and treated at the Department of ENT and Head and Neck Surgery, Zadar General Hospital, Zadar, Croatia. The tumor was surgically removed. Unfortunately, the patient died one year after the procedure due to multiorgan failure. Although metastases of renal cell carcinoma to the head and neck are very rare, it should be first suspected when investigating a metastatic tumor in this region. Surgical excision offers the best hope for long term survival. In case of unresectable tumor, other treatment options should be considered such as radiotherapy, immunotherapy and chemotherapy.

Entities:  

Mesh:

Year:  2015        PMID: 26415321

Source DB:  PubMed          Journal:  Acta Clin Croat        ISSN: 0353-9466            Impact factor:   0.780


  3 in total

1.  Metastatic Renal Cell Carcinoma Presenting as a Paranasal Sinus Mass: The Importance of Differential Diagnosis.

Authors:  Massimo Ralli; Giancarlo Altissimi; Rosaria Turchetta; Mario Rigante
Journal:  Case Rep Otolaryngol       Date:  2017-01-11

Review 2.  Multiple metastases of clear-cell renal cell carcinoma to different region of the nasal cavity and paranasal sinus 3 times successively: A case report and literature review.

Authors:  Na Zhang; Bing Zhou; Qian Huang; Xiaohong Chen; Shunjiu Cui; Zhenxiao Huang; Yan Sun
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

3.  Identification of key genes of the ccRCC subtype with poor prognosis.

Authors:  Grigory Andreevich Puzanov
Journal:  Sci Rep       Date:  2022-08-26       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.